Incyte (INCY) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
Incyte's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Incyte's ROA in the third quarter of 2026? Incyte Corporation achieved a return on average assets (ROA) of 5.48 % in its third quarter of 2026, this is above INCY's average return on assets of -0.83%. Incyte Corporations assets during the 12 months ending in the third quarter of 2026 are valued at $7 billion
ROA decreased relative to the period ending Jun 30 2026, due to the decline in net income.
However, within the Healthcare sector 144 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 206, from total ROA ranking in the second quarter of 2026 at 240.
Wilmington, Delaware Incyte Corporation (Nasdaq: INCY) has unveiled pivotal clinical results from the Phase 1 study of its bispecific antibody TGFR2PD-1 (INCA33890), aimed at targeting advanced colorectal cancer, alongside a breakthrough oral inhibitor of KRAS G12D mutations (INCB161734) for advanced pancreatic ductal adenocarcinoma (PDAC). These developments mark significant strides in addressing critical cancer types that currently have limited treatment options. Innovative Treatment ApproachesThe bispecific antibody TGFR2PD-1 is designed to engage both TGFβ and PD-1 pathways, potentially enhancing the immune system s capability to detect and attack colorectal cancer cells that exhibit microsatellite stability (MSS). MSS colorectal cancer represents a challenging segment to treat due to its lower likelihood of responding to typical immunotherapy approaches. The initial clinical data presented highlight the promising efficacy of this dual-targeting strategy, suggesting a new frontier in immune-oncology treatments.
Incyte Unveils Pioneering Oncology and Dermatology Data at Major 2024 Medical Conferences By , CSIMarket.com WILMINGTON, Del. Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company famed for its innovative approach to drug development, is making waves in the medical research community with a series of significant data presentations at prominent conferences throughout 2024. From the realms of oncology to dermatology, Incyte is setting the stage for advancements that could reshape treatment paradigms across several challenging conditions.This December, at the American Society of Hematology (ASH) Annual Meeting in San Diego, Incyte is poised to offer a comprehensive view of its oncological portfolio, highlighted by a much-anticipated presentation on Tafasitamab. This CD19-targeted immunotherapy, currently in testing for its efficacy against follicular lymphoma, promises to deliver insights that may refine therapeutic approaches for this hematological malignancy. Incyte s strategic communication emphasizes that the details disclosed will be benchmarked against the original statements, maintaining the integrity and validity required for critical clinical evaluations.
Comment on INCY's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 18.49 % compared to prior year, due to annual net income growth of 3844.96 % to $1,286.65 million, while value of Incyte's overall assets grew just by 27.8 % to $6,957.97 million, compared to $6,957.97 a year before.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
